The third-generation EGFR TKI AZD9291, which can overcome T790M-mediated TKI resistance, significantly suppressed the tumor growth in H1975 xenografts, but had a weak effect on A549 xenograft tumors. The gene discussed is EGFR; the disease is neoplasm.